LioCyx-M
Phase 2Biologic
LioCyx-M is one of 59 biologic programs targeting Chronic Hepatitis. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
71 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1Viread
GileadApproved
PEG-Intron
Merck & Co.Phase 3
Emtriva
GileadApproved
Glucophage
EMD SeronoApproved
Opdivo
Bristol-Myers SquibbPhase 2
Pegylated Interferon Alfa
Merck & Co.Phase 3
NA Therapy
GSKPhase 3
AHB-137
AAusper Biopharma Co., Ltd.
Phase 3
Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
Azvudine
HHenan Genuine Biotech Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LioCyx-M. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- LLion TCR Pte. Ltd.